Drug Trial Radar · NCT06904105
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
556
Actual
Start
Apr 10, 2025
Primary completion
Apr 17, 2026
Study completion Jun 12, 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.
Conditions
- Overweight
- Obesity
Interventions
HRS-7535 TabletsDrug
HRS-7535 tablets.
HRS-7535 Placebo TabletsDrug
HRS-7535 placebo tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight relative to the baselineTime frame: 44th week after administration.
- Proportion of participants with a body weight reduction of ≥ 5% relative to the baselineTime frame: 44th week after administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.